En Carta Diagnostics raised €5 million ($5.7 million) in private financing to advance its aptamer-based molecular platform, including its EC Pocket Lyme point-of-care test. The funding includes €3 million in equity from investors including Blue Forest Ventures and Ring Capital, plus €2 million in nondilutive support from Bpifrance and others. The company said it will use the capital for US and European regulatory clearances, ramping manufacturing through partner Circum Medical, and commercializing its Lyme test while preparing additional diagnostic products.